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Abstract: Carotid intima-media thickness (IMT) and plaques have been shown to have a strong 
continuous relationship with cardiovascular (CV) morbidity and mortality; therefore, carotid 
atherosclerosis, as assessed by ultrasonography, can be regarded as a reliable surrogate end-point 
for therapeutic interventions. In this survey, we report the results of 16 double blind, randomized, 
controlled studies comparing: 1) antihypertensive drugs versus placebo/no treatment (five trials 
including 3,215 patients); 2) different active antihypertensive drug regimens (five trials including 
4,662 patients); 3) angiotensin-II receptor blockers (ARBs) versus other antihypertensive agents 
(six trials including 841 patients). Our main findings can be summarized as follows: I) Long-term 
antihypertensive treatment has a blunting effect on carotid IMT progression, regardless of types 
of drugs. II) Calcium-channel blockers (CCBs) are more effective than other antihypertensive 
drugs including diuretics, beta-blockers, and angiotensin converting-enzyme (ACE)-inhibitors 
in this blunting effect; III) the effect of ARBs compared to other antihypertensive regimens 
(mostly based on atenolol) on carotid atherosclerosis progression needs to be further elucidated, 
as a protective effect was demonstrated by some, but not all studies examined. Thus, further 
studies are needed to clarify the role of ARBs in this therapeutic area.
Keywords: ultrasonography, carotid atherosclerosis, antihypertensive drugs, angiotensin II 
receptor blockers
Introduction
Numerous studies based on high-definition ultrasound scanning of carotid arteries have 
demonstrated an association between intima-media thickness (IMT) and cardiovascular 
(CV) risk factors,1–3 preclinical CV alterations such as left ventricular hypertrophy, 
cerebral white matter lesions, peripheral arterial atherosclerosis, microalbuminuria, 
coronary calcifications4–7 and, more importantly, overt CV diseases.8 In particular, high 
blood pressure (BP) has been shown to be a major risk factor for carotid IM thicken-
ing and plaque progression,9 due to the synergistic effect of mechanical stress on the 
arterial wall and growth/inflammatory factors operating in hypertension.
Prospective studies in population-based samples and selected cohorts of individu-
als at high risk have demonstrated that diffuse and focal alterations in carotid artery 
walls are strong predictors of CV morbidity and mortality.10–12
Owing to the predictive power of carotid ultrasound alterations, guidelines for the 
management of arterial hypertension from major International scientific bodies such as 
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and World Health Organization (WHO)/International Society 
of Hypertension recommend carotid examination for a better 
stratification of total CV.13,14
Carotid IMT has been shown to be a valuable surrogate 
end-point for assessing the antiatherogenic effects of thera-
peutic interventions,15 in particular in clinical trials testing 
the efficacy of antihypertensive and cholesterol-lowering 
drugs.
In this paper, we review the studies published in the 
last decade in which IMT was measured in order to assess 
the impact of antihypertensive drugs on carotid structure; 
focusing on the following questions in particular: 1) does 
antihypertensive treatment affect IMT progression? 2) do 
different classes of antihypertensive drugs have different 
antiatherogenic properties? 3) do ARBs have a role in reduc-
ing asymptomatic carotid atherosclerosis or in slowing down 
its progression? Before addressing this issue, however, some 
more general considerations on the clinical and prognostic 
value of carotid IMT are needed.
Intima-media thickness as a marker 
of CV risk
The refined methodologies now available allow to detect and 
measure preclinical structural and functional alterations of 
the CV system. Ultrasonic assessment of the carotid artery 
structure has attracted considerable interest in this field and 
is largely applied either for clinical and research purposes.16 
In the mid 80’s, Pioneer studies by Pignoli and colleagues17 
investigated the correlation of ultrasonic interfaces with 
anatomical components of the arterial wall; they demon-
strated that IM complex, namely the lumen-intima and 
media-adventitia boundary, which appears as a double-line 
pattern at the ultrasound examination, provides a reliable 
measurement of the arterial based on both histological and 
gross pathological comparisons. Since then, hundreds of 
cross-sectional studies have been performed in order to 
assess the prevalence and distribution of carotid atheroscle-
rosis and its association with CV risk factors.1,18 In essential 
hypertensives, a significant increase in IMT has been reported 
as compared with age-matched normotensive controls, after 
adjustment for several confounding variables.19 Studies in 
population and hypertensive cohorts have consistently shown 
that systolic and pulse pressure are significantly correlated 
to the degree of carotid thickness.20–22
A number of prospective trials, including the Atheroscle-
rotic Risk in Communities (ARIC),23 the Rotterdam Study,24 
the Cardiovascular Health Study (CHS),25 the European 
Lacidipine Study on Atherosclerosis (ELSA)26 and the 
Carotid Atherosclerosis Progression Study (CAPS)27 have 
reported that carotid IMT and/or plaques are strong predic-
tors of coronary events and stroke.
In the ARIC study the relation of carotid IMT with the 
incidence of coronary heart disease (CHD) was assessed 
over a 4–7 years follow-up in 7,289 women and 5,552 
men aged 45–64 years and free from CHD at baseline.23 
Incident events were 96 in women and 194 in men; in sex-
specific Cox proportional hazards models, the hazard ratio 
for IMT values 1 mm versus 1 mm was 5.07 in women 
(95% confidence interval [CI]: 3.08–8.36) and 1.85 in men 
(95% CI: 1.28–2.69).
The Rotterdam Study investigated the prognostic value 
of carotid plaques in predicting stroke in a population-based 
survey including 4,217 asymptomatic subjects aged 55 years 
or older.24 The presence of carotid plaques at six locations of 
the arteries was assessed at baseline; after an average follow-
up of 5.2 years, 160 strokes had occurred. The presence of 
carotid plaques, irrespective of their location, increased by 
50% the risk of stroke.
Among the 5,858 elderly participants in the CHS, the 
incidence of CV events, in particular the relative risk of 
myocardial infarction (MI) or stroke, correlated with carotid 
IMT (p  0.001).25 The relative risk of MI or stroke adjusted 
for age and sex in the highest thickness quintile as compared 
with the lowest one was 3.87 (95% CI: 2.72–5.51). The 
association between CV events and IMT remained signifi-
cant after adjusting for traditional risk factors; the results of 
separate analyses of MI and stroke paralleled those for the 
combined end point.
In the ELSA study, including 2,334 patients with uncom-
plicated hypertension, death, MI, major and all CV events had 
an increased incidence in the highest carotid IMT quintile and 
in groups with the greatest number of plaques at baseline.26 
The risk increase compared to the lowest quintile was about 
fivefold, when considering IMT, and threefold after adjust-
ing for age, gender, clinical systolic blood pressure (SBP), 
and treatment.
In the CAPS study common carotid artery (CCA) IMT 
and vascular risk factors have been evaluated at baseline in 
5,056 participants (mean age 50.1 years) and the incidence 
of stroke, MI, and death was determined prospectively over 
a mean follow-up period of 4.2 years.27 IMT was highly 
predictive of all end points (eg, hazard rate ratios per 1 SD 
CCA-IMT increase were 1.43 [95% CI: 1.35–1.51] for 
MI, 1.47 [95% CI: 1.35–1.60] for stroke, and 1.45 [95% 
CI: 1.38–1.52] for MI, stroke, or death; p  0.0001 for all). 
The predictive value of IMT remained significant for MI and Integrated Blood Pressure Control 2009:2 
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the combined end point, after adjustment for age, sex, and 
vascular risk factors.
Overall, these trials indicate that carotid IMT and plaques 
have a strong continuous relationship with MI, stroke, and 
CV death, the relationship remaining significant after adjust-
ment for major traditional risk factors.
Effects of antihypertensive  
drugs on IMT
Since the mid 90s, a number of trials have compared the 
effects of different antihypertensive drugs on carotid IMT 
and plaque progression in a variety of clinical conditions 
(ie, CHD, asymptomatic carotid artery disease, diabetes, 
dyslipidemia, hypertension, and preclinical renal disease). 
A limited fraction of these studies, however, provided 
reliable information. Studies evaluating drug effects on IMT 
progression should follow strict methodological criteria: 
include enough subjects (at least 100–200 per treatment arm) 
to detect small but clinically relevant between-treatment 
differences, have a long-term follow-up (at least 1 year) 
and apply reading protocols minimizing the regression to the 
mean and readers’ bias.
In this review, we describe the results of 16 double-
blind, randomized controlled studies divided in three 
groups according to the study design comparing: I) anti-
hypertensive drugs with placebo or no treatment (five trials 
including 3,215 patients); II) active antihypertensive drug 
regimens based on diuretics, beta-blockers, CCBs and ACE 
inhibitors (five trials including 4,662 patients); III) ARBs 
versus other antihypertensive agents (six trials including 
841 patients). Studies reported in trials comparing antihy-
pertensive drugs versus placebo and trials comparing active 
antihypertensive drug regimens (Tables 1 and 2) fulfill all 
the aforementioned criteria; this was not the case for the 
studies reported in ARBs versus other antihypertensive 
drugs (Table 3), which also included trials with 40 
patients per treatment arm.
Trials comparing antihypertensive  
drugs versus placebo
These trials mostly tested the protective effects of ACE-
inhibitors on carotid atherosclerosis, as these drugs have been 
shown to reduce coronary events in various patient groups 
and to prevent atherosclerosis in animal models.
In the Prevention of Atherosclerosis with Ramipril 
(PART 2), 617 patients with coronary, cerebrovascular or 
peripheral vascular disease were randomized to ramipril 
(5–10 mg daily) or placebo.28 Carotid atherosclerosis was 
assessed at baseline as well as after two and four treatment 
years: BP was reduced by 6 mmHg systolic and 4 mmHg 
diastolic in the ramipril compared to the placebo group 
(p  0.001); no significant difference, however, was found 
between groups in the changes of CCA far wall thickness or 
carotid plaque score from baseline to follow-up.
The Prospective Randomized Evaluation of the Vascular 
Effects of Norvasc Trial (PREVENT) was a multicenter, ran-
domized, placebo-controlled trial designed to test the slowing 
effect of amlodipine in the progression of early coronary 
Table  randomized controlled trials comparing the effects on carotid IMT of different antihypertensive drugs versus placebo/no 
treatment with a minimum numerosity of 100 patients per treatment arm
Trial/Setting/Drug  Ref.  Subjects (n)  Primary outcome  Duration 
(years)
Results 
PART - 
CHD, cerebrovascular, and peripheral 
disease ramipril/no-treatment
28 617 IMT changes and plaque score 4 No difference
SECURE 
Diabetes, vascular disease, ramipril/ 
placebo
30 732 IMT changes 4.5 ramipril more  
effective
PREVEND 
Patients with microalbuminuria,  
fosinopril/placebo
31 642 IMT changes 4 No difference
BCAPS 
Patients with asymptomatic  
carotid plaque, metoprolol/placebo
32 793 IMT changes 3 Metoprolol more   
effective
PREVENT 
Sub-study CHD, amlodipine/placebo
29  377  IMT changes  3  Amlodipine more   
effective
Abbreviations: CHD, coronary heart disease; IMT, intima-media thickness.Integrated Blood Pressure Control 2009:2 
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atherosclerosis in 825 patients with angiographically 
documented CHD.29 Secondary aim of  the study in a subgroup 
of 377 patients was to investigate the CCB impact on the 
rate of atherosclerosis progression in carotid arteries. Amlo-
dipine significantly slowed-down carotid atherosclerosis 
progression during the 36-month study period: the placebo 
group, indeed, experienced a 33-mm IMT increase, whereas 
a 126-mm decrease was observed in the amlodipine group 
(p = 0.007).
The Study to Evaluate Carotid Ultrasound changes in 
patients treated with ramipril and vitamin E (SECURE) 
was a prospective double-blind trial evaluating the effects 
of long-term treatment (average follow-up 4.5 years) with 
ramipril (2.5–10 mg/day) and vitamin E on atherosclerosis 
progression in 732 patients aged 55 years, affected by 
vascular disease or diabetes plus, at least, another risk 
factor.30 The progression slope of the mean maximum 
carotid IMT was 21.7 mm/year in the placebo group, 
18.0 mm/year in the ramipril 2.5 mg/daily group and 
13.7 mm/year in the ramipril 10 mg/daily group (p = 0.033), 
thus indicating that ramipril beneficially affects atheroscle-
rosis progression.
The Prevention of Renal and Vascular ENdstage Interven-
tion Trial (PREVEND) assessed fosinopril and pravastatin 
Table  randomized controlled trials comparing the effects on carotid IMT of different antihypertensive drugs with a minimum numerosity 
of 100 patients per treatment arm
Trial/Setting/Drug  Ref.  Subjects (n)  Primary outcome  Duration  
(years)
Results 
MIDAS 
essential hypertension, israpidine/HCTZ
34 883 IMT changes 3 No difference
VHAS 
essential hypertension, verapamil/
chorthalidone
35 498 IMT changes 4 verapamil more effective
INSIGHT 
essential hypertension, nifedipine/ 
co-amilozide
36 439 IMT changes 4 Nifedipine more effective
ELSA 
essential hypertension,  
lacidipine/atenolol
26 2334 IMT changes and plaque  
progression
4 Lacidipine more effective
PHYLLIS 
essential hypertension, dyslipidemia,  
fosinopril/HCTZ
37 
 
508 
 
IMT changes 
 
2.6 
 
Fosinopril more effective 
 
Abbreviations: HCTZ, hydrochlorothiazide; IMT, intima-media thickness.
Table  Trials comparing the effects carotid IMT of ArBs versus other antihypertensive drugs, with a minimum numerosity of 40 patients 
per treatment arm
Trial/Setting/Drug  Ref.  Subjects (n)  Primary outcome  Duration 
(years)
Results 
LAARS 
essential hypertension, losartan/atenolol
40 280 IMT changes 2 No difference
SILVHIA 
essential hypertension, irbesartan/atenolol
41 108 IMT changes 1 Irbesartan more effective
Ariff et al 
essential hypertension, candesartan/atenolol
42 88 IMT changes 1 Candesartan more 
effective
Ichihara et al 
essential hypertension, valsartan/amlodipine
43 100 IMT changes 1 No difference
MORE 
essential hypertension and carotid plaque,  
olmesartan/atenolol
44 165 IMT and plaque changes 4 No difference
Ono et al 
essential hypertension, candesartan/no ArB
45  100  IMT changes  2  Candesartan more 
effective
Abbreviations:   ArB, angiotensin-receptor blockers; IMT, intima-media thickness.Integrated Blood Pressure Control 2009:2 
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effects on carotid IMT in subjects with increased urinary 
albumin excretion (UAE; 15 to 300 mg/24 h). Measurement 
of IMT was performed at baseline and after four years in 
642 subjects randomized to fosinopril 20 mg or matching 
placebo and to pravastatin 40 mg or matching placebo; 31 
overall IMT progression rate was 37 ± 6 mm, no significant 
differences were found among fosinopril, pravastatin, and 
placebo.
The Beta-blocker Cholesterol-Lowering Asymptomatic 
Plaque Study (BCAPS) compared low-dose metoprolol 
(25 mg daily), fluvastatin (40 mg daily) and placebo 
effects on carotid IM progression during a 36-month treat-
ment period in 793 subjects with asymptomatic carotid 
plaques.32 At the study end, IMT (mean) progression rate 
of common carotid was reduced by fluvastatin (-9 mm/y; 
95% CI: -15 to -3; p = 0.002). At both 18 and 36 months, 
IMT (max) progression in the carotid bulb was reduced 
by metoprolol (-58 mm/y, 95% CI: -94 to -23; p = 0.004 
and -23 mm/y, 95% CI: -44 to -3; p = 0.014, respectively), 
thus reflecting a favorable beta-blocker effect on atheroscle-
rosis progression.
Finally, in a recent meta-analysis including all the 
above mentioned trials plus four smaller studies, Wang 
and coworkers have shown that antihypertensive treatment 
significantly reduced IM thickening rate by 7 mm/year 
compared with placebo (p = 0.01).33
Trials comparing active antihypertensive 
drug regimens
The Multicenter Isradipine Diuretic Atherosclerosis Study 
(MIDAS) was the first prospective trial investigating this area 
by comparing the effects of a twice daily dose of isradipine 
(2.5–5 mg) and hydrochlorothiazide (HCTZ) (12.5–25 mg) 
in 883 patients with mild to moderate hypertension and maxi-
mum IMT of 1.17 ± 0.20 mm (=1170 ± 200 mm).34 The study 
primary end point, namely the rate of mean maximum IMT 
progression in 12 carotid sites over three years (30 mm/year), 
did not differ between the treatment groups (p = 0.68). Since 
patients randomized to HCTZ achieved significantly lower 
BP levels than their counterparts, the lack of differences in 
IMT progression between treatment arms was considered as 
an indirect evidence of a protective effect of isradipine on 
the carotid artery wall.
In the Verapamil in Hypertension and Atherosclerosis 
Study (VHAS) 498 hypertensive patients, randomized to 
either verapamil (240 mg daily) or chlorthalidone (25 mg 
daily), underwent carotid ultrasound examinations at base-
line and after 3, 12, 24, 36, and 48 months of treatment.35 
The primary endpoint for treatment efficacy, namely the IMT 
change slope over four years (rate of change, mm/year), was 
significantly different between treatment groups (verapamil 
-82 mm/year versus chlorthalidone -37 mm/year; p  0.02). 
As the BP-lowering effect of the two randomized treatments 
was similar, these findings indicate the verapamil is more 
effective than chlorthalidone in promoting regression of 
carotid atherosclerosis.
The International Nifedipine GITS Study: Intervention 
as a Goal in Hypertension Treatment (INSIGHT) assessed 
common carotid IMT progression in 439 hypertensives 
randomized to nifedipine 30 mg or co-amilozide (HCTZ 
25 mg and amiloride 2.5 mg) for a four-year follow-up 
period.36 Ultrasonography was performed at baseline, at four 
months, and subsequently every year. Primary outcome was 
IMT progression rate (slope of IMT-time regression): this 
parameter differed between treatment groups either before 
(p = 0.002) as after (p = 0.003) adjustment for baseline 
covariates and BP changes. In particular, nifedipine retarded 
the progression of carotid wall changes as compared to 
coamilozide, despite similar BP-lowering effects.
The European Lacidipine Study on Atherosclerosis 
(ELSA), a randomized double-blind trial in 2,334 hyperten-
sive patients, tested the effects of a four-year treatment with 
lacidipine or atenolol on mean maximum IMT in common 
carotid arteries and bifurcations.26 Yearly IMT progression 
rate was 14.5 mm/y in atenolol-treated and 8.7 mm/y in 
lacidipine-treated patients (p = 0.001); plaque progression 
was significantly less common, and plaque regression was 
significantly more frequent in the lacidipine group. Clinic BP 
was similarly reduced by both treatments, whereas 24-hour 
ambulatory systolic/diastolic BP changes were greater 
in the atenolol- (-10/-9 mm Hg) than lacidipine-group 
(-7/-5 mm Hg). A greater efficacy of lacidipine on carotid 
IMT and plaque progression despite a smaller ambulatory 
BP reduction, supports an antiatherosclerotic action of 
lacidipine which is partially independent of the antihyper-
tensive effect.
The Plaque Hypertension Lipid-Lowering Italian Study 
(PHYLLIS) was designed to test whether: 1) fosinopril 
(20 mg per day) was more effective than HCTZ (25 mg 
per day) on carotid atherosclerosis progression; 2) pravastatin 
(40 mg per day) was more effective than placebo when added 
to either HCTZ or fosinopril; 3) the ACE inhibitor and statin 
had additive antiatherosclerotic effects.37
Five hundred and eight hypertensive hypercholester-
olemic patients with asymptomatic carotid atherosclerosis 
were randomized to the following treatments: (A) HCTZ, Integrated Blood Pressure Control 2009:2 
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(B) fosinopril, (C) HCTZ plus pravastatin, (D) fosinopril 
plus pravastatin and followed-up for 2.6 years. The primary 
outcome was the change in mean maximum IMT of far 
and near common carotid walls and bifurcations bilaterally 
(CBMmax). CBMmax significantly progressed (10 ± 4 mm/year; 
p = 0.01) in group A compared to the remaining groups; 
CBMmax changes in group B, C, and D were significantly 
lower than in group A. Clinic and ambulatory BP reductions 
were not different among groups, whereas total and low-
density lipoprotein cholesterol decreased by approximately 
1 mmol/L in group C and D. These results show that both 
fosinopril and pravastatin exert an antiatherosclerotic action, 
although they do not provide any evidence about an additive 
effect of their combination on IMT progression.
ArBs versus other antihypertensive drugs
Experimental and clinical studies indicate that ARBs exert 
antiatherogenic antiproliferative effects over and beyond 
their antihypertensive action.38,39 Scarce evidence, however, 
is available about the properties of these drugs in prevent-
ing carotid atherosclerosis progression. Due to the limited 
number of studies available, also trials with a numerosity of 
at least 40 patients per treatment-arm and a follow-up of at 
least one year have been included in this section.
The Losartan Vascular Regression Study (LAARS) 
investigated the effects of losartan (50 mg once daily) and 
atenolol (50 mg once daily) on CCA IMT in 280 patients 
with mild to moderate essential hypertension and right or left 
CCA IMT between 0.8 and 1.5 mm at baseline.40 Primary 
end point of the study was the yearly rate of change (YRC) 
of mean IMT in CCA (CCA-IMTmean) from baseline over 
two years treatment. Target BP (SBP/diastolic blood pres-
sure [DBP]  140/90 mm Hg) was achieved by sequentially 
adding HCTZ 12.5 mg once daily, doubling the dose of the 
study drug, or adding an open-label CCB, as needed.
Both losartan and atenolol induced comparable 
reductions in SBP/DBP and CCA-IMT mean over the 
24 months period compared to baseline; average YRC 
was -38 ± 04 mm/y for losartan (p  0.001) and -37 ± 4 mm/y 
for atenolol (p  0.001).
In the Swedish Irbesartan Left Ventricular Hypertrophy 
Investigations versus Atenolol (SILVHIA) study 108 hyper-
tensive patients with LV hypertrophy were randomized double-
blind to irbesartan (n = 52) or atenolol (n = 56) treatment 
for 48 weeks.41 Ultrasonographic CCA and echocardiographic 
examinations were performed at baseline and at the study 
end. In front of similar blood pressure reductions, CCA 
IMT tended to decrease with irbesartan (-10 ± 100 mm 
from 920 ± 140 mm, NS), whereas it increased with atenolol 
(+30 ± 120 mm from 940 ± 210 mm; p = 0.018; with p = 0.002 
between groups).
Ariff and colleagues compared the effects of a 52-week 
candesartan-based (8–16 mg daily) and atenolol-based 
(50–100 mg daily) regimen on CCA and LV structure in 
88 hypertensive patients in a randomized, double-blind study. 
HCTZ (12.5–25 mg/day), felodipine (5–10 mg/day), and 
doxazosin (4–16 mg/day) were added as required.42 Clinic 
and 24-hour ambulatory BP, left ventricular (LV) mass index, 
CCA IMT, lumen diameter, IM area, carotid blood flow and 
distensibility were measured at baseline, at 26 and 52 weeks 
of treatment. Both candesartan and atenolol similarly reduced 
IMT and IM area and increased carotid distensibility after 
52 weeks. Atenolol-based treatment, however, but not can-
desartan-based treatment was associated with CCA inward 
remodeling, as reflected by a reduction of lumen diameter.
Ichihara and colleagues investigated the long-term effects 
of 24-h ambulatory BP control with amlodipine versus valsar-
tan on vascular damage in untreated hypertensive patients.43 
Pulse wave velocity (PWV), carotid arteries IMT, and 24-h 
ambulatory BP were determined in 100 untreated hyperten-
sive patients before and after a 12-month treatment.
Amlodipine and valsartan similarly decreased ambulatory 
BP and PWV; neither drug altered maximum carotid artery 
IMT, which averaged 920 ± 50 and 880 ± 40 mm, respectively, 
at baseline.
The Multicentre Olmesartan atherosclerosis Regres-
sion Evaluation (MORE) study, a double-blind trial in 
hypertensive patients at increased CV risk due to carotid 
wall thickening and atherosclerotic plaques, compared the 
effects of a two-year treatment based on either olmesartan 
or atenolol on CCA IMT and plaque volume (PV) deter-
mined by two- and three-dimensional (3D) ultrasound 
examinations.44 A total of 165 patients randomized to either 
olmesartan (20–40 mg/day) or atenolol (50–100 mg/day) 
underwent carotid ultrasonography at baseline, 28, 52, and 
104 weeks of treatment. The primary efficacy outcome was 
the change from baseline (Delta) in CC-IMT assessed by 2D 
ultrasound examination; secondary outcomes included Delta 
in PV assessed by 3D ultrasound and in BP. Olmesartan 
and atenolol produced comparable significant reduc-
tions in CC-IMT; mean Delta IMT was -90 ± 15 mm for 
olmesartan and -82 ± 14 mm for atenolol. Mean Delta PV 
was -4.4 ± 2.3 mL and 0.1 ± 1.5 mL in the olmesartan and 
atenolol group, respectively, without significant between-
treatment differences. In the subgroup of patients with 
baseline PV greater than or equal to median value (33.7 mL), Integrated Blood Pressure Control 2009:2 
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significant between-treatment differences existed in Delta PV 
(p = 0.023), as PV regressed with olmesartan (–11.5 ± 4.4 mL) 
and was unchanged with atenolol (0.6 ± 2.5 mL), thus sug-
gesting that olmesartan exerts a more protective effect in 
advanced carotid atherosclerosis. Ono and colleagues evalu-
ated the effects of antihypertensive therapy on NO produc-
tion, oxidative stress and carotid IMT in 100 hypertensive 
patients randomized to candesartan 8 mg (plus CCBs, ACE 
inhibitors, and/or beta-blockers, when needed) or to treatment 
with all drugs above mentioned other than ARB.45 Carotid 
IMT was assessed before and after 12 and 24 months of 
treatment. Urine levels of 8-hydroxy-2’-deoxyguanosine 
(8-OHdG), an oxidative stress indicator, and serum levels 
of NOx, as a marker of NO were measured. BP similarly 
decreased below 140/90 mmHg in both groups.
Carotid IMT significantly decreased after 12 and 
24 months of treatment in the ARB group, but not in the non-
ARB group; this decrement was associated with a parallel 
decrease of 8-OHdG and an increase of NOx levels.
Conclusions
A solid body of evidence indicates that carotid IM thickening 
and plaques are important added risks for CV events in 
different clinical settings, regardless of BP and conventional 
risk factors. Thus, carotid atherosclerosis can be regarded as 
a reliable surrogate end-point for therapeutic interventions. 
The main findings of our review may be summarized as 
follows. I) Carotid IMT progression is blunted by long-term 
antihypertensive treatment: compared with placebo or no 
treatment, an ACE-inhibitor,28 a beta-blocker,31 and a CCB29 
slightly reduced IMT progression rate in high risk patients 
with type 2 diabetes, CHD, and vascular disease. II) CCBs 
are more effective than other antihypertensive drugs in this 
respect: actively controlled studies show that CCBs retarded 
IMT progression more effectively than diuretics,34,35 beta-
blocker,26 and ACE-inhibitor.37 The antiatherosclerotic effect 
of CCBs, shown in these clinical trials, is also supported by 
the demonstrated efficacy of these agents in various animal 
models of atherosclerosis.46,47 Possible specific mechanisms 
for the antiatherosclerotic effect of CCBs are inhibited 
production of reactive oxygen species and reduced expression 
of adhesion molecules in endothelial cells, and restoration of 
endothelial function.48 III) Limited evidence is available, so 
far, for ARBs and further studies are needed to clarify role of 
these drugs in this therapeutic area. In fact, an ARB protective 
effect against the progression of carotid atherosclerosis was 
shown by three out of six studies examined, comparing irbe-
sartan versus atenolol,41 candesartan versus atenolol,42 and 
no-ARB antihypertensive therapy.45 Minor protective effects 
favoring ARBs over the beta-blocker atenolol has been also 
demonstrated in the LAARS40 and MORE44 studies.
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